RE: Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival from a Phase III Trial

Journal of the National Cancer Institute

Volumn 107, Issue 9, 2015, Pages

  Velu, Lavanniya K Palani ^a,b   Steele, Colin W ^b   Dickson, Euan J ^b   Carter, C Ross ^b   McKay, Colin J ^b   Horgan, Paul G ^a,b   McMillan, Donald C ^a,b   Jamieson, Nigel B ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GEMCITABINE; JANUS KINASE; PACLITAXEL; RUXOLITINIB; STAT PROTEIN; ANTINEOPLASTIC AGENT;

CANCER PROGNOSIS; HUMAN; INFLAMMATION; LETTER; LONG TERM SURVIVAL; METASTATIC PANCREATIC CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; ADENOCARCINOMA; FEMALE; LIVER NEOPLASMS; MALE; MORTALITY; PANCREATIC NEOPLASMS;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; PANCREATIC NEOPLASMS;

EID: 84942255162     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv204     Document Type: Letter

References (7)

1. Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107(2):dju413 doi:10.1093/jnci/dju413.
2. Jamieson NB, Denley SM, Logue J, et al. A prospective comparison of the prognostic value of tumor-and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2011;18(8):2318-2328.
3. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of infammation-based prognostic scores in patients with cancer. A Glasgow Infammation Outcome Study. Eur J Cancer. 2011;47(17):2633-2641.
4. Dienstmann R, Rodon J, Barretina J, et al. Genomic medicine frontier in human solid tumors: prospects and challenges. J Clin Oncol. 2013;31(15):1874-1884.
5. Denley SM, Jamieson NB, McCall P, et al. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adeno-carcinoma. J Gastrointest Surg. 2013;17(5):887-898.
6. Hurwitz HI, Uppal N, Wagner SA, et al. A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol. 2014;32:5s.
7. Alvarez R, Musteanu M, Garcia-Garcia E, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer. 2013;109(4):926-933.